A new method measuring the interaction between von Willebrand factor and coagulation factor VIII

Area of Science:

• Hematology
• Clinical Chemistry
• Immunology

Background:

• Accurate measurement of coagulation factor VIII (FVIII) binding to von Willebrand factor (VWF) in plasma is crucial for clinical diagnostics.
• Existing methods for assessing FVIII-VWF interaction in routine clinical settings require improvement in reliability.

Purpose of the Study:

• To develop and validate a reliable enzyme-linked immunosorbent assay (ELISA) for quantifying FVIII binding to VWF directly in plasma samples.
• To assess the diagnostic utility of the developed assay in identifying FVIII-VWF binding defects, particularly in patients with von Willebrand disease.

Main Methods:

• Coating microtiter plates with an anti-FVIII antibody (ESH-8) targeting the C2 domain.
• Incubating wells with recombinant FVIII, followed by diluted plasma samples.
• Quantifying bound VWF using HRP-conjugated anti-VWF antibodies.

Main Results:

• The developed ELISA demonstrated a strong signal in response to VWF concentration.
• Plasma from patients with various von Willebrand disease types often showed diminished FVIII-VWF binding.
• Correction for VWF antigen levels revealed that only patients with type 2N von Willebrand disease had significantly abnormal binding ratios. Healthy individuals showed a mean corrected ratio of 0.94 ± 0.15.

Conclusions:

• A simple, reliable ELISA method for detecting reduced FVIII-VWF binding in plasma has been established.
• This assay is suitable for large-scale population studies and identifying subtle binding defects in patients.
• The method offers improved diagnostic capabilities for FVIII-VWF related bleeding disorders.